Zhiwei Microbial Medicine

Zhiwei Microbial Medicine is a China-based biotechnology company focused on the research and development of live biotherapeutic products (LBPs) derived from the human microbiota. The company leverages a proprietary microbial drug discovery platform to identify and characterize specific bacterial strains with therapeutic potential for metabolic, immune, and neurological disorders. Their pipeline primarily targets high-prevalence conditions such as type 2 diabetes and obesity through the modulation of the gut-organ axes. Zhiwei aims to translate microbiome science into standardized, pharmaceutical-grade microbial therapies to address unmet medical needs in chronic disease management.